Dr. Emmanuelle Charpentier
Dr. Emmanuelle Charpentier is a Scientific Member and Director at the Max Planck Institute for Infection Biology in Berlin. Prior to joining Max Planck, Emmanuelle held an Alexander von Humboldt professorship at the Helmholtz Centre for Infection Research and Hannover Medical School, Germany. She continues to oversee a research group at the Laboratory for Molecular Infection Medicine at Umeå University, Sweden where she has a visiting professorship. Her seminal research unveiled the key mechanisms of the CRISPR-Cas9technology, laying the foundation for the use of CRISPR-Cas9 as a highly versatile and precise gene editing tool. Emmanuelle studied biochemistry and microbiology at the University Pierre-and-Marie-Curie in Paris, France where she received her Ph.D. in microbiology for her research performed at the Pasteur Institute. She spent five years working in the U.S., where she held research associate positions at the Rockefeller University, New York University Langone Medical Center, the Skirball Institute of Biomolecular Medicine and St. Jude Children’s Research Hospital. Before taking up her current positions, Emmanuelle was heading a microbiology research group at the Max F. Perutz Laboratories at the University of Vienna in Austria. Emmanuelle’s work has been recognized by numerous awards including the Breakthrough Prize in Life Sciences, the Carus Medal awarded by the Leopoldina German Academy of Sciences, the Gruber Prize in Genetics, the Princess of Asturias Award for Technical and Scientific Research, the Louis Jeantet Prize for Medicine, the Ernst Jung Prize for Medicine, the Göran Gustafsson Prize awarded by the Royal Swedish Academy of Sciences, Le Prix Jean-Pierre Lecocq from the French Academy of Sciences, the L’Oréal Unesco for Women in Science Award 2016, the 2015 Otto Warburg Medal, the Umeå University EC Jubilee Award 2015 (named for her) and the 2015 Hansen Family Award. Emmanuelle was also recognized by TIME as one of The Most Influential People in 2015.